458 terminated. 458 Phase 2, 55 Phase 3, 37 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 458 | Terminated 458 |
| Phase 3 | 55 | Terminated 55 |
| Phase 1 | 37 | Terminated 37 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sex Differences in Neurobehavioral Response to THC Dronabinol, Placebo - Cannabis Use Disorder | Phase 2 | Terminated | Medical University of South Carolina | 5 | 2026-04-27 | 2026-10-06 |
| The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g - Postoperative Delirium | Phase 2 | Terminated | University of Missouri-Columbia | 1 | 2026-03-03 | 2026-05-11 |
| Extension Study of Participants From SPG302-ALZ-101 SPG302 - Alzheimer's Disease | Phase 2 | Terminated | Spinogenix | 12 | 2025-03-25 | 2025-12-18 |
| A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder NRCT-101SR, NRCT-202XR - ADHD | Phase 2 | Terminated | Neurocentria, Inc. | 2 | 2025-02-25 | 2026-01-15 |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) MK-1167, Placebo - Alzheimer Disease, Dementia | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 369 | 2024-12-16 | 2026-07-01 |
| A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder TMP-301, Placebo - Alcohol Use Disorder (AUD) | Phase 2 | Terminated | Tempero Bio, Inc. | 110 | 2024-11-14 | 2026-04-13 |
| Efficacy and Safety of HB-1 for Panic Disorder HB-1, Telmisartan Only Product in Oral Dose Form, Verapamil Only Product in Oral Dose Form - Panic Disorder, Mental Illness | Phase 2 | Terminated | HB BioTech, LLC | 170 | 2024-10-29 | 2026-09-24 |
| Cannabidiol for Reducing Drinking in Alcohol Use Disorder Cannabidiol oral oil, Placebo oral oil - Alcohol Use Disorder | Phase 2 | Terminated | Hôpital le Vinatier | 10 | 2024-10-25 | 2026-06-12 |
| Study of ASN51 in Adults With Early Alzheimer's Disease ASN51, Placebo - Alzheimer Disease | Phase 2 | Terminated | Asceneuron S.A. | 123 | 2024-10-16 | 2025-06-29 |
| Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD) Lemborexant, Placebo - Major Depressive Disorder(MDD), Insomnia Comorbid to Psychiatric Disorder | Phase 2 | Terminated | Unity Health Toronto | 30 | 2024-09-25 | 2026-07-30 |
| Ultrasonic Neuromodulation for Treatment of Cognitive Impairment Diadem prototype - Alzheimer Disease, Dementia | Phase 1 / Phase 2 | Terminated | University of Utah | 1 | 2024-08-18 | 2025-05-25 |
| Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) TNX-1300 (Injection), Placebo (Injection) - Cocaine Use, Cocaine Intoxication | Phase 2 | Terminated | Tonix Pharmaceuticals, Inc. | 3 | 2024-08-16 | 2025-06-24 |
| SAINT for MDD in an Inpatient Setting Follow-on Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| BHV-7000 Open-Label Extension Bipolar Mania Study BHV-7000 - Bipolar Disorder | Phase 2 | Terminated | Biohaven Therapeutics Ltd. | 94 | 2024-06-24 | 2025-12-16 |
| Ketamine for OUD and Suicidal Ideation in the ED Ketamine, Saline Solution - Opioid Use Disorder, Suicidal Ideation | Phase 2 | Terminated | Brigham and Women's Hospital | 4 | 2024-06-14 | 2025-04-08 |
| Lavender Aromatherapy to Decrease Anxiety/Pain Perception During Office Hysteroscopy Lavandula angustifolia, Aura Cacia, Placebo - Anxiety, Pain, Procedural | Phase 2 | Terminated | University of Florida | 22 | 2024-06-01 | 2026-06-10 |
| Ultrasonic Neuromodulation for Treatment of PTSD Diadem - PTSD | Phase 1 / Phase 2 | Terminated | University of Utah | 10 | 2024-04-05 | 2025-05-25 |
| Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients SHR-1707, SHR-1707 placebo - Alzheimer's Disease | Phase 2 | Terminated | Shanghai Hengrui Pharmaceutical Co., Ltd. | 46 | 2024-02-05 | 2026-05-13 |
| Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD NRCT-101SR - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Terminated | Neurocentria, Inc. | 95 | 2024-01-25 | 2026-01-15 |
Showing 20 of 458. Sign in to see all of them.
Alzheimer Disease (84) · Schizophrenia (51) · Depressive Disorder, Major (48) · Depression (41) · Stress Disorders, Post-Traumatic (29) · Alcoholism (23) · Dementia (22) · Bipolar Disorder (21) · Cognitive Dysfunction (21) · Anxiety Disorders (19) · Opioid-Related Disorders (18) · Tobacco Use Disorder (17) · Psychotic Disorders (16) · Autism Spectrum Disorder (15) · Attention Deficit Disorder with Hyperactivity (11)
Nervous System Diseases (160) · Neurocognitive Disorders (124) · Central Nervous System Diseases (118) · Brain Diseases (115) · Neurodegenerative Diseases (104) · Dementia (86) · Chemically-Induced Disorders (83) · Tauopathies (81) · Behavior (75) · Substance-Related Disorders (75) · Pathological Conditions, Signs and Symptoms (72) · Mood Disorders (70) · Signs and Symptoms (59) · Schizophrenia Spectrum and Other Psychotic Disorders (54)
Ketamine (15) · Sugars (9) · Midazolam (8) · Quetiapine Fumarate (8) · Donepezil (7) · Risperidone (6) · Exercise (5) · Sertraline (5) · Sodium Chloride (5) · nabiximols (5) · pozanicline (5) · Buprenorphine (4) · Dronabinol (4) · Methylphenidate (4) · N-Methyl-3,4-methylenedioxyamphetamine (4)
New York State Psychiatric Institute (13) · Pfizer (13) · National Institute of Mental Health (NIMH) (12) · Merck Sharp & Dohme LLC (10) · Yale University (9) · GlaxoSmithKline (8) · Janssen Research & Development, LLC (8) · Novartis Pharmaceuticals (7) · University of Pennsylvania (7) · VA Office of Research and Development (7) · AstraZeneca (6) · H. Lundbeck A/S (6) · National Institute on Drug Abuse (NIDA) (6) · The University of Texas Health Science Center, Houston (6) · AbbVie (5)
United States (327) · Canada (65) · United Kingdom (39) · Germany (37) · France (36) · Spain (32) · Australia (26) · Netherlands (21) · Poland (21) · Japan (20) · Italy (15) · Belgium (14) · South Korea (12) · Denmark (11) · Sweden (11)
Carlos A Zarate, M.D. (3) · Jessica Harder, MD (3) · Alan Breier, MD (2)
PMID 27789188, PMID 28433500, PMID 29480210, PMID 32250312, PMID 35704951, PMID 39637767, PMID 40603145, PMID 18413705, PMID 18671864, PMID 18827129, PMID 20074703, PMID 20707781, PMID 21199966, PMID 21346607, PMID 21799479, PMID 22050051, PMID 22394471, PMID 22689694, PMID 23364679, PMID 23483886, PMID 23734252, PMID 23794107, PMID 23920422, PMID 24482677, PMID 25054836, PMID 25257291, PMID 25328711, PMID 25422883, PMID 25427171, PMID 25554563, PMID 25645373, PMID 25669746, PMID 25689146, PMID 25733754, PMID 25887557, PMID 25890643, PMID 25973909, PMID 26414022, PMID 26493637, PMID 26967214, PMID 27319970, PMID 27366831, PMID 27752075, PMID 27756421, PMID 27767991, PMID 27807285, PMID 27871675, PMID 28006970, PMID 28044255, PMID 28157809
2014 (5), 2015 (4), 2016 (4), 2017 (4), 2019 (4), 2008 (2), 2009 (2), 2018 (2), P50DA009262 (2), 1IK2CX001397-01A2 (1), 1UF1AG046150-01 (1), 2023 (1), 271201100006I-0-27100007-1 (1), I01CX001761 (1), I01CX001789 (1)